PERNIX THERAPEUTICS HOLDINGS, INC. (NASDAQ:PTX) Files An 8-K Other EventsItem 8.01 Other Events
Third Supplemental Indenture
On December 29, 2017, Pernix Therapeutics Holdings, Inc. (the “Company”) and U.S. Bank National Association, as trustee, entered into a third supplemental indenture (the “Third Supplemental Indenture”) to that certain indenture dated as of August 19, 2014, as amended and supplemented from time to time (the “Senior Secured Notes Indenture”) with the consent of the holders of a majority in aggregate principal amount of its outstanding 12.0% Senior Secured Notes due 2020 issued under the Senior Secured Notes Indenture. The Third Supplemental Indenture amends the Senior Secured Notes Indenture to clarify the definition of “Net Sales”, as such term is defined in the Senior Secured Notes Indenture.
The foregoing description of the Third Supplemental Indenture does not purport to be complete and is subject to, and is qualified in its entirety by reference to, the full text of the document which is attached hereto as Exhibit 4.1 to this Current Report onForm 8-K,and is incorporated herein by reference.
| Item 9.01. | Financial Statements and Exhibits. |
(d)Exhibits
PERNIX THERAPEUTICS HOLDINGS, INC. ExhibitEX-4.1 2 dp84552_ex0401.htm EXHIBIT 4.1 Exhibit 4.1 PERNIX THERAPEUTICS HOLDINGS,…To view the full exhibit click here
About PERNIX THERAPEUTICS HOLDINGS, INC. (NASDAQ:PTX)
Pernix Therapeutics Holdings, Inc. is a specialty pharmaceutical company. The Company focuses on identifying, developing and commercializing differentiated products that address unmet medical needs. It focuses on underserved therapeutic areas, such as central nervous system (CNS), including neurology and psychiatry, as well as other specialty therapeutic areas. Its products include Treximet, indicated for acute migraine; Zohydro ER with BeadTek, an extended-release opioid agonist indicated for the management of pain severe; Silenor for the treatment of insomnia characterized by difficulty with sleep maintenance, and Khedezla for major depressive disorder. It promotes selected non-core branded products, such as its cough and cold products, through co-promotion arrangements with third-party sales organizations, and distributes its generic products through its subsidiaries, Macoven Pharmaceuticals, LLC (Macoven) and Cypress Pharmaceuticals, Inc.